

iDEAS
Imaging Dementia—Evidence
For Amyloid Scanning

Study Investigators

Gil D. Rabinovici, MD, *Principal Investigator*

Maria C. Carrillo, PhD

Constantine Gatsonis, PhD

Bruce Hillner, MD

Barry A. Siegel, MD

Rachel A. Whitmer, PhD

Dear Research Participant:

You are considering participation in the research study conducted by American College of Radiology Imaging Network (ACRIN) and the Alzheimer's Association called "Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study."

The purpose of this letter is to inform you the enrollment goal for Aim 1 (11,050) has been met. Study enrollment will continue to enable completion of Aim 2 of the study; participants registered to the study after July 31, 2017 will continue to be referred for a PET scan but a 90 day post-PET follow-up visit will not be required.

In addition, the informed consent form states your doctor will complete two forms about your diagnosis and treatment plan; one before the amyloid PET scan and one 90 days after the scan. However, now that the study has moved to Aim 2 there is no 90 day post-PET visit or form completion required for participants enrolled after July 31, 2017.

The American College of Radiology and the Alzheimer's Association thank you and fully recognize the value of your participation in this important research study.

Sincerely,

Cynthia Olson, Project Manager, on behalf of
Gil Rabinovici, MD, Principal Investigator and the IDEAS Study Team